Status: Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: PMV Pharmaceuticals, IncUpdated: Jun 26, 2026Locations: 77
Eligibility criteria
At least 18 years of age or 12 to 17 years of age after Safety Review Committee... [+7]
Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug [+22]